3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
abemaciclib
3
Fulvestrant
3
Anastrozole
3
ribociclib
2
palbociclib
2
exemestane
2
Tamoxifen
2
Letrozole
2
trastuzumab deruxtecan
1
taxane
1
pertuzumab
1
elacestrant
1
dalpiciclib
1
Trastuzumab
1
STX-478
1
RAD1901
1
Metformin
1
Leflunomide
1
Imlunestrant
1
Gonadotropin-Releasing Hormone
1
Genotype
1
Body Height
1
Blood Pressure
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Diseases
×
STX-478
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled